The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part A) and a multiple ascending dose (MAD) part (Part B). A total of 56 participants will be randomized in this study (35 in the SAD part, 21 in the MAD part).~SAD Part: Participants will be randomized to receive a single oral dose of LABP-104 (250 mg, 500 mg, 750 mg, 1000 mg or 1500 mg) or placebo after a 6-hour fast.~MAD Part: Participants will be randomized to receive LABP-104 (250 mg, 750 mg, or 1500 mg) or placebo once daily for 7 days after a 6-hour fast.
This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study. The primary objective of this study is to assess the safety and tolerability of single and 7-day repeat oral doses LABP-104 in healthy adult volunteers.